Found 180 with Last Name = 'parsons' and Initial = 'wj' TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.530nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.530nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.590nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.590nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.690nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.690nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.730nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.730nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.840nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.840nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.950nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.950nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.70nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.70nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.5nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.5nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.30nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.30nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
